Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.43
Industry P/E
--
Debt to Equity
0.01
ROE
-1.54 %
ROCE
-149.9 %
Div. Yield
0 %
Book Value
7.49
EPS
-14.44
CFO
$-118.65 Mln
EBITDA
$-169.83 Mln
Net Profit
$-156.51 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Palisade Bio (PALI)
| -56.37 | -28.01 | -56.63 | -87.86 | -75.08 | -68.85 | -70.98 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Palisade Bio (PALI)
| 177.33 | -88.65 | -92.00 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug... PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. Address: 7750 El Camino Real, Carlsbad, CA, United States, 92009 Read more
CEO, CFO & Director
Mr. J. D. Finley
CEO, CFO & Director
Mr. J. D. Finley
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Palisade Bio Inc (PALI) stood at $ 11 Mln as on 31-Dec-24
The share price of Palisade Bio Inc (PALI) is $0.72 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Palisade Bio Inc (PALI) has given a return of -75.08% in the last 3 years.
Palisade Bio Inc (PALI) has a market capitalisation of $ 3 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Palisade Bio Inc (PALI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Palisade Bio Inc (PALI) and enter the required number of quantities and click on buy to purchase the shares of Palisade Bio Inc (PALI).
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. Address: 7750 El Camino Real, Carlsbad, CA, United States, 92009
The CEO & director of Mr. J. D. Finley. is Palisade Bio Inc (PALI), and CFO & Sr. VP is Mr. J. D. Finley.
There is no promoter pledging in Palisade Bio Inc (PALI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Palisade Bio Inc. (PALI) | Ratios |
|---|---|
|
Return on equity(%)
|
-153.55
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Palisade Bio Inc (PALI) was $0 Mln.
$0.02
(
